![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of this agreement, Axantia will register, hold the marketing authorization and commercialize Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Razumab
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Intas Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 04, 2022